Article
Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
European journal of medical research - 27 Oct 2008
Katsounas A, Jochum C, Canbay A, Schlaak J, Gerlich W H, Gerken G
Abstract excerpt
BACKGROUND: In chronic hepatitis B patients undergoing therapy with LAM or ADV, viral breakthrough is possible due to the emergence of drug resistance. LAM resistant HBV strains are susceptible to ADV, while ADV resistant mutants remain sensitive to LAM. CASE REPORT: A male patient with HBV-relat...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.